Market Intelligence, Clinical Progress, and High-Purity Reagents for Next-Generation CD47 Axis Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SIRPG/CD172g drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SIRPG ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. HEK293 Expressed (Native Glycosylation). Sequence Verified. |
View SIRPG Products |
| Gene Delivery | SIRPG Promise-ORF / Lentivirus Full-length ORF for stable T-cell or NK-cell line construction. |
View SIRPG Products |
| Benchmark Ab | Anti-SIRPG (Sequence of Research Grade Clone) Recombinant positive control for binding specificity. |
View SIRPG Products |
| Validator | SIRPG siRNA Set For knockdown verification and specificity confirmation. |
View SIRPG Products |
| SIRPA/CD172a | SIRPA ECD-Fc Protein Family homolog for selectivity screening (critical off-target check). |
View SIRPA Products |
| CD47 | CD47 Recombinant Protein Ligand for binding competition and affinity characterization assays. |
View CD47 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SIRP Family Selectivity (SIRPG vs SIRPA) | Homolog Panel Proteins strictly verified by Mass Spec; Human SIRPG and SIRPA ECD-Fc available with distinct tag strategies for simultaneous detection |
| Cross-species Cyno/Mouse Eval | Human/Mouse/Cyno ortholog proteins available with >95% purity; Sequence alignment verified for epitope conservation |
| CD47 Binding Affinity Quantification | High-purity CD47 (H-tag/Avi-tag) for SPR/BLI; Theoretical MW confirmed by SDS-PAGE |
| Cell Surface Expression Validation | Lentivirus Premade Particles (titer >1E8 TU/mL) for stable integration in Jurkat/Primary T-cell models |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and scrambled siRNA included |
Live SIRPG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD47/SIRP axis therapeutics is intensifying. First-generation pan-SIRP inhibitors can inadvertently block SIRPG on T cells, compromising anti-tumor immunity. The next wave of R&D is targeting SIRPG-selective blockade to enhance T-cell and NK-cell cytotoxicity without the systemic macrophage disruption associated with SIRPA targeting. SIRPG emerges as a compelling T-cell restricted alternative, offering distinct biology from the myeloid-focused SIRPA. As first-generation CD47 and SIRPA antibodies face toxicity and hematological challenges, the industry is pivoting toward alternative checkpoint nodes.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-SIRPG mAb | Early-stage biotech / Academic consortia | Solid Tumors, Hematologic Malignancies | Selectivity vs SIRPA (Need SIRPG/SIRPA ortholog panel) |
| SIRPG x CD3 Bispecific | Preclinical developers | T-cell Lymphoma, Solid Tumors | Heterodimer Validation (Need full-length SIRPG Lentivirus) |
| SIRPG-targeted ADC | Emerging IO platforms | CD47-refractory Tumors | Internalization Assay (Need high-purity ECD-Fc) |
| Combination (IO) | Research consortia | Refractory Solid Tumors | Co-culture assay reagents (Need SIRPG + CD47 proteins) |
Molecular Differentiation & Assay Strategy
Targeting SIRPG requires extreme selectivity and precise epitope mapping. Key strategies include:
- Affinity & Epitope: Target unique IgV domain epitopes of SIRPG to avoid cross-reactivity with SIRPA.
- Selectivity: Use homolog protein panels (SIRPA, SIRPB1) for rigorous counter-screening.
- Cross-species: Validate binding to human, cynomolgus monkey, and mouse SIRPG for toxicology support.
- Cell-based Assays: Lentiviral constructs for stable cell lines enable flow cytometry and functional co-culture studies.
TarMart provides the full toolkit: HEK293-expressed SIRPG ECD-Fc (native glycosylation, >95% purity), lentiviral particles, benchmark antibodies, siRNA, and SIRPA/CD47 proteins for seamless assay integration.